metastatic brain cancer

(redirected from secondary brain cancer)

metastatic brain cancer

A brain tumour arising from metastatic malignancy.

Primary sites
Lung, breast, colon, kidney, melanoma.
References in periodicals archive ?
I lost my partner of 26 years seven weeks ago to lung and secondary brain cancer.
When you consider the broad anti-cancer activity of TRXE-009, combined its ability to kill cancer stem cells, and now combined with its confirmed ability to get it across the blood-brain barrier, TRXE-009 in our view represents an exciting drug prospect and a breakthrough in the search for an avenue of treatment for the large unmet clinical need of both primary and secondary brain cancer," Kelly added.
But his condition rapidly deteriorated a fortnight ago when doctors discovered he had developed secondary brain cancer.
But she was diagnosed with terminal lung and secondary brain cancer in April, before she had a chance to use them.
But in addition to a general anti-cancer use, the ultimate objective is to see it tested in adults and children with brain cancers, and people with secondary brain cancer associated with cancers such as melanoma.
the development of lead SBP drug candidate, TRXE-009, as a treatment of both primary and secondary brain cancer in adults and children, including glioblastoma and medulloblastoma;
My father died having a coronary bypass graft operation after years of smoking probably fewer than five cigarettes a day; a close friend died in his wife's arms in front of me with secondary brain cancers from a carcinoma of the lung caused directly by smoking, and I have seen patients die from mouth cancer, lung cancer, bladder cancer, stroke, ruptured aortic aneurysm, peripheral vascular disease, chronic bronchitis and emphysema - all caused by, or exacerbated by, smoking.
Secondary brain cancers arise when cancer in other tissues spreads (metastasises) to the brain: an estimated 98,000--170,000 cases occur each year in the US, with metastases to the brain seen in 24-45% of all cancer patients.
A phase I trial in the UK will recruit patients with a variety of solid tumours, while a US investigator-led trial will enrol patients with primary or secondary brain cancers.
The data to be presented relate to the potential safety, efficacy and utility of ANG1005 in primary and secondary brain cancers.
The urgent need to find a successful treatment for devastating cancers such as primary and secondary brain cancers in adults and children is what is driving our collaboration with Feinstein to bring TRXE-009 into the clinic," Kelly added.
Presenting also will be Professor Gil Mor (Yale Medical School) who will review the pre-clinical research leading to the development of Cantrixil, the first chemotherapy specifically designed for the treatment of cancer of body cavities, and Dr Marc Symons (Feinstein Medical Research Institute) who will review the pre-clinical program to bring TRXE-009 into the clinic for the treatment of adult and pediatric primary and secondary brain cancers.